Home / Research library / RAD-140
RAD-140: molecular data, studies & sources
RAD-140 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
Molecular record not yet resolved
A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.
MF: not assigned · MW: not assigned · Structure: not assigned
Registered clinical trials
Studies registered on ClinicalTrials.gov that list RAD-140 as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
1 registered study matched.
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast CancerNCT03088527 · start 2017-10-23 · primary completion 2020-08-28 | Phase 1Completed | Hormone Receptor Positive Malignant Neoplasm of Breast | Stemline Therapeutics, Inc.20 participants |
Registry check 2026-10-01 · Run this search on ClinicalTrials.gov
Human and clinical studies
Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.
No matching human study was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Case report
Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033).
Barbara M, Dhingra S, Mindikoglu AL et al. · ACG case reports journal · 2020
PMID 33062783 · DOI: 10.14309/crj.0000000000000409
- Case report
Myopericarditis Following Use of Selective Androgen Receptor Modifier "RAD-140".
Schwartzman KH, Kohli U, Chaudhuri NR et al. · JACC. Case reports · 2024
PMID 39157568 · DOI: 10.1016/j.jaccas.2024.102423
- Preclinical / laboratory research
Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses.
Cheung HW, Wong KS, To NS et al. · Drug testing and analysis · 2021
PMID 33277807 · DOI: 10.1002/dta.2988
- Research publication · design requires review
Unregulated gains: a case of RAD-140-induced liver injury.
Dao D, King B, Dao H et al. · Proceedings (Baylor University. Medical Center) · 2026
PMID 42417499 · DOI: 10.1080/08998280.2026.2691619
- Research publication · design requires review
Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes.
Wagener F, Euler L, Görgens C et al. · Metabolites · 2022
PMID 35888790 · DOI: 10.3390/metabo12070666
- Preclinical / laboratory research
Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats.
Jayaraman A, Christensen A, Moser VA et al. · Endocrinology · 2014
PMID 24428527 · DOI: 10.1210/en.2013-1725
- Case report
Selective androgen receptor modulator abuse-induced heart failure: catastrophic effects of RAD-140 (Testolone).
Skorupski WJ, Marko A, Janus M et al. · Polish archives of internal medicine · 2024
PMID 38864168 · DOI: 10.20452/pamw.16770
- Case report
Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone).
Padappayil RP, Chandini Arjun A, Vivar Acosta J et al. · Cureus · 2022
PMID 35233331 · DOI: 10.7759/cureus.21663
RAD-140 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.
Reference sources & further reading
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Andarine (S4)
Molecular identity needs further verification
5 selected publications · 0 human study records
Cardarine
Molecular identity needs further verification
8 selected publications · 0 human study records · 3 registered trials
LGD-4033
Molecular identity needs further verification
8 selected publications · 1 human study records · 1 registered trials
MK-677
C27H36N4O5S
528.7 g/mol · PubChem CID 178024
2 selected publications · 2 human study records · 4 registered trials
MK-777 (Acetamoren)
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human study records
Ostarine
C19H14F3N3O3
389.33 g/mol · ChEMBL CHEMBL1738889
8 selected publications · 0 human study records · 17 registered trials
Small molecule · highest stage: Phase 3